Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezurock Phase 1 Safety and PK in Healthy Volunteers
NCT05918614Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing KD025 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events and serious adverse events up to 58 days. Started Mar 2014; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05918614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918614.